Haemonetics Revenue vs. Net Income

HAE Stock

USD 58.58 -0.32 -0.54%

Based on Haemonetics' profitability indicators, Haemonetics is yielding more profit at this time than in the previous quarter. Current readings indicate it has a moderate probability of reporting better profitability numbers in April. Profitability indicators assess Haemonetics' ability to earn profits and add value for shareholders.

Total Revenue

First Reported

1990-06-30

Previous Quarter

327.3 M

Current Value

339 M

Quarterly Volatility

89.8 M

Macro event markers

Oil Shock

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Interest Hikes

Based on recent performance metrics, Sales General And Administrative To Revenue is expected to edge higher. A year ago, Haemonetics reported Sales General And Administrative To Revenue at 0.32. As of now, The current year's Days Of Sales Outstanding is projected to rise to 77.02, while EV To Sales are moving lower toward 2.23. Comparative financial data indicate that Net Income is shifting by roughly 4.76%. A year ago, Haemonetics reported Net Income at 192.83 Million. As of now, The current year's Income Before Tax is projected to rise to approximately 256.1 M, while Total Other Income Expense Net is moving lower toward about -11.8 M. Pretax Profit Margin is evolving in line with broader financial reporting trends. A year ago, Haemonetics reported Pretax Profit Margin at 0.12. As of now, The current year's Operating Profit Margin is projected to rise to 0.13, while Net Profit Margin is moving lower toward 0.08.

Current Value

Last Year

Change From Last Year

10 Year Trend

Gross Profit Margin

0.57

0.5438

Sufficiently Up

Slightly volatile

Net Profit Margin

0.0834

0.0898

Significantly Down

Slightly volatile

Operating Profit Margin

0.13

0.126

Sufficiently Up

Slightly volatile

Pretax Profit Margin

0.12

0.116

Sufficiently Up

Slightly volatile

Return On Assets

0.0694

0.0535

Significantly Up

Slightly volatile

Return On Equity

0.11

0.1225

Moderately Down

Slightly volatile

The profitability profile for Haemonetics reflects how income compares to revenue, assets, and capital. The relationship between margins and returns reflects operational efficiency over time.

Build portfolio with Haemonetics Stock

Revenue by Earning Segment

Haemonetics' revenue is distributed across 6 distinct product categories. Hospital accounts for approximately 26.6% of Haemonetics' revenue at 143.5 Million, while Plasma contributes 25.8% at 138.91 Million. Revenue is well distributed across segments, limiting Haemonetics' exposure to disruption in any one product area.

Risk vs Return Analysis.

For information on how to trade Haemonetics Stock refer to our How to Invest in Haemonetics guide.Projected EPS for Haemonetics is 1.27, with a low-high corridor of 1.23 to 1.25. The latest trailing EPS is 3.63, allowing a direct check of consensus level versus realized earnings base. The consensus EPS view for Haemonetics usually references EPS before non-recurring items. These estimates can include stock-based compensation expense.

Macro event markers

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Interest Hikes

Haemonetics consensus EPS is set at 1.27 for the 31st of March 2026 reporting period. Historical volatility context supplements the analyst consensus view for Haemonetics..

Haemonetics Revenue by Earnings Segment Overview

Haemonetics' product-level revenue split is shown below, highlighting each segment's share of total revenue. Interventional Technologies, Hospital rounds out the mix at 10.4%, representing Haemonetics' smallest reported product line.

Earnings estimates provide context for forward-looking performance discussion. The estimates are provided as neutral context for research workflows and timeframe comparisons.

Quarterly Earnings Growth

0.284

Earnings Share

3.63

Revenue Per Share

27.509

Quarterly Revenue Growth

-0.03

Return On Assets

0.0645

The gap between Haemonetics' market value and book value reflects how the market perceives future potential versus historical cost. Haemonetics' market capitalization is 2.74 B. Haemonetics P/B of 2.99 shows the market assigns a modest premium over accounting equity. Enterprise value stands at 3.58 B. The relationship between Haemonetics' intrinsic value, market price, and book value adds depth to the analysis.

Haemonetics' estimated value and market price are complementary but separate measures of worth. Haemonetics' trading price represents the transaction level agreed by market participants.

Haemonetics Net Income vs. Revenue Fundamental Analysis

Comparative market metrics assess Haemonetics's pricing relative to peers.

Haemonetics is rated below average for revenue relative to top peers. It holds the #2 position for net income relative to top peers with a Net Income-to-Revenue ratio near 0.12 . The Revenue to Net Income ratio for Haemonetics comes in at 8.12 . Total Revenue is showing structural movement consistent with an increasing trend. A year ago, Total Revenue was sitting at 1.56 Billion. Valuation multiples such as P/E, P/B, and P/S compare Haemonetics to peer earnings performance.

Haemonetics Revenue vs. Competition

Haemonetics is rated below average for revenue relative to top peers. Market size based on revenue of Health Care industry is currently estimated at about 24.96 Billion. Haemonetics holds roughly 1.36 Billion in revenue claiming about 5% of equities under Health Care sector.

Revenue Workforce Capitalization Valuation Total debt

Haemonetics Net Income vs. Revenue

Revenue is income that a firm generates from business activities such as rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.

Haemonetics

Revenue

Money Received

-

Discounts and Returns

1.36 B

Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.

Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.

Haemonetics

Net Income

(Rev + Gain)

-

(Exp + Loss)

167.68 M

Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.

Haemonetics Net Income Comparison

Haemonetics is currently under evaluation for net income relative to top peers.

Haemonetics Profitability Projections

A key trait of a strong company is its ability to earn a profit, and for Haemonetics investors this matters a lot. Profit progress for Haemonetics blends several ratios, where stable trends suggest steady results. Haemonetics currently maintains a profit margin of 13.3%. A rising operating margin signals that Haemonetics' core business is getting more efficient. The operating margin stands at 21.0% while return on equity is 19.3%. The profit trend below reflects Haemonetics' results across the most recent reporting periods. Recent net income of 167.7 M reflects the bottom-line result of these profitability dynamics.

	Last Reported	End Of Year Estimate
Accumulated Other Comprehensive Income	-63.3 M	-60.2 M
Operating Income	255.1 M	267.8 M
Total Other Income Expense Net	-11.2 M	-11.8 M
Net Income	192.8 M	202.5 M
Income Before Tax	243.9 M	256.1 M
Income Tax Expense	51.1 M	53.6 M
Net Income Applicable To Common Shares	192.8 M	202.5 M
Net Income From Continuing Ops	192.8 M	202.5 M
Non Operating Income Net Other	-13.2 M	-13.8 M
Interest Income	11.2 M	13.2 M
Net Interest Income	-8.8 M	-9.2 M
Change To Netincome	41.6 M	40.4 M
Net Income Per Share	2.32	2.43
Income Quality	1.55	1.47
Net Income Per E B T	0.77	0.44

Haemonetics Profitability Driver Comparison

Profitability drivers are factors that directly affect the investment outlook for Haemonetics. Investors holding Haemonetics' stock face unpredictable events that can materially affect the company's earnings.

Earnings Estimation Breakdown

The calculation of Haemonetics' earnings per share is based on data from the past 12 consecutive months used for reporting the company's financial figures. The next projected EPS of Haemonetics is estimated to be 1.27 with the future projection ranging from a low of 1.2325 to a high of 1.245. Please be aware that this consensus of annual earnings estimates for Haemonetics is based on EPS before non-recurring items.

Last Reported EPS

0.95

1.23

Lowest

Expected EPS

1.27

1.25

Highest

Earnings Projection Consensus

A consensus EPS-based estimate above Haemonetics' current price may suggest the market is pricing in excessive pessimism or overlooking near-term catalysts. Conversely, an estimate below market price could reflect a premium valuation that requires sustained earnings growth to justify. Both interpretations demand risk assessment and should not be acted upon in isolation.

Number of Analysts	Historical Accuracy	Last Reported EPS		Estimated EPS for 31st of March 2026	Current EPS (TTM)
11	89.16%	0.95		1.27	3.63

Earnings History

Earnings estimate consensus by Haemonetics analysts from Wall Street is used by the market to judge Haemonetics' stock performance. Investors also use these earnings estimates to evaluate and project the stock performance into the future in order to make their investment decisions. However, we suggest analyzing not only Haemonetics' upcoming profit reports and earnings-per-share forecasts but also comparing them to our different valuation methods.

Haemonetics Quarterly Gross Profit

191.41 Million

Based on recent performance metrics, Earnings Yield are expected to edge lower. A year ago, Earnings Yield were sitting at 0.03. As of now, The current year's Price Earnings To Growth Ratio is projected to rise to 17.43, while Retained Earnings are moving lower toward about 285 M. As of now, The current year's Net Income Applicable To Common Shares is projected to rise to approximately 202.5 M, while Common Stock Shares Outstanding is moving lower toward about 42.5 M.

Experienced market participants anticipate that Haemonetics' price will even out over time. Periods when Haemonetics' deviates significantly from its historical mean may warrant further fundamental analysis.

Hype

Prediction

Low	Estimated	High
56.59	58.58	60.57

Details

Intrinsic

Valuation

Low	Real	High
52.34	54.33	64.44

Details

Naive

Forecast

Low	Next	High
52.89	54.88	56.87

Details

Analyst

Consensus

Low	Target	High
79.63	87.50	97.13

Details

Analyzing Haemonetics in isolation is insufficient for informed investment decisions. This peer-relative view often uncovers mispricing that single-company analysis would miss. Major investment banks and asset managers with significant Haemonetics exposure routinely update their models around earnings events. Their collective positioning and reaction to consensus deviations often define the immediate post-earnings trend. For short-term traders, this institutional sensitivity to consensus makes the EPS surprise the single most watched event variable.

Earnings per Share Projection vs Actual

When Haemonetics reports actual EPS, investors compare it against the analyst consensus estimate for Haemonetics to judge performance. A beat versus consensus is typically interpreted as positive execution; a miss signals a shortfall relative to expectations. EPS is expressed on a weighted average per-share basis to account for equity changes within the reporting period.

Estimated Months Earnings per Share

EPS serves income investors in Haemonetics as a quick gauge of dividend affordability: the higher the EPS relative to the dividend per share, the more cushion management has. However, accounting EPS can diverge from cash-based earnings, so investors should validate EPS signals with operating cash flow and capex data. Comparing Haemonetics' EPS to sector peers provides further context for dividend sustainability.

Quarterly Analyst Estimates and Surprise Metrics

Earnings surprise history for Haemonetics' reveals whether the company tends to guide conservatively or struggles to meet analyst expectations. A pattern of consistent beats signals strong management execution; repeated misses may indicate structural challenges. Analyst EPS estimates are formed from a combination of forward guidance, sector trends, and macroeconomic inputs.

Reported	Fiscal Date	Estimated EPS	Reported EPS	Surprise
2026-02-05	2025-12-31	0.9	0.95	0.05	5
2025-11-06	2025-09-30	1.11	1.27	0.16	14
2025-08-07	2025-06-30	1.02	1.1	0.08	7
2025-05-08	2025-03-31	1.22	1.24	0.02	1
2025-02-06	2024-12-31	0.91	0.74	-0.17	18
2024-11-07	2024-09-30	0.77	0.66	-0.11	14
2024-08-08	2024-06-30	1.01	1.02	0.01	0
2024-05-09	2024-03-31	0.89	0.9	0.01	1
2024-02-08	2023-12-31	0.94	1.04	0.1	10
2023-11-02	2023-09-30	0.89	0.99	0.1	11
2023-08-08	2023-06-30	0.73	1.05	0.32	43
2023-05-11	2023-03-31	0.7	0.77	0.07	10
2023-02-07	2022-12-31	0.82	0.85	0.03	3
2022-11-07	2022-09-30	0.67	0.83	0.16	23
2022-08-10	2022-06-30	0.51	0.58	0.07	13
2022-05-10	2022-03-31	0.6	0.65	0.05	8
2022-02-08	2021-12-31	0.73	0.84	0.11	15
2021-11-09	2021-09-30	0.61	0.6	-0.01	1
2021-08-11	2021-06-30	0.45	0.5	0.05	11
2021-05-13	2021-03-31	0.67	0.46	-0.21	31
2021-02-02	2020-12-31	0.65	0.81	0.16	24
2020-11-04	2020-09-30	0.51	0.62	0.11	21
2020-08-04	2020-06-30	0.41	0.46	0.05	12
2020-05-05	2020-03-31	0.73	0.69	-0.04	5
2020-02-04	2019-12-31	0.76	0.94	0.18	23
2019-11-01	2019-09-30	0.72	0.87	0.15	20
2019-08-06	2019-06-30	0.64	0.81	0.17	26
2019-05-07	2019-03-31	0.55	0.61	0.06	10
2019-02-05	2018-12-31	0.59	0.63	0.04	6
2018-11-06	2018-09-30	0.54	0.56	0.02	3
2018-08-07	2018-06-30	0.42	0.59	0.17	40
2018-05-08	2018-03-31	0.43	0.43	0.0	0
2018-02-06	2017-12-31	0.44	0.62	0.18	40
2017-11-07	2017-09-30	0.41	0.48	0.07	17
2017-08-07	2017-06-30	0.3	0.33	0.03	10
2017-05-08	2017-03-31	0.38	0.39	0.01	2
2017-02-06	2016-12-31	0.4	0.43	0.03	7
2016-11-07	2016-09-30	0.35	0.46	0.11	31
2016-08-01	2016-06-30	0.29	0.25	-0.04	13
2016-05-02	2016-03-31	0.46	0.37	-0.09	19
2016-02-01	2015-12-31	0.45	0.48	0.03	6
2015-11-04	2015-09-30	0.4	0.44	0.04	10
2015-07-27	2015-06-30	0.31	0.35	0.04	12
2015-04-27	2015-03-31	0.52	0.47	-0.05	9
2015-01-29	2014-12-31	0.51	0.53	0.02	3
2014-11-03	2014-09-30	0.45	0.47	0.02	4
2014-07-30	2014-06-30	0.35	0.38	0.03	8
2014-04-28	2014-03-31	0.58	0.46	-0.12	20
2014-01-27	2013-12-31	0.6	0.61	0.01	1
2013-10-28	2013-09-30	0.55	0.66	0.11	20
2013-07-29	2013-06-30	0.39	0.46	0.07	17
2013-05-01	2013-03-31	0.46	0.48	0.02	4
2013-01-30	2012-12-31	0.48	0.5	0.02	4
2012-10-29	2012-09-30	0.39	0.45	0.06	15
2012-08-01	2012-06-30	0.35	0.28	-0.07	20
2012-04-29	2012-03-31	0.42	0.4	-0.02	4
2012-01-30	2011-12-31	0.4	0.43	0.03	7
2011-10-31	2011-09-30	0.39	0.36	-0.03	7
2011-08-01	2011-06-30	0.39	0.33	-0.06	15
2011-05-02	2011-03-31	0.42	0.43	0.01	2
2011-01-31	2010-12-31	0.41	0.45	0.04	9
2010-11-01	2010-09-30	0.38	0.4	0.02	5
2010-08-02	2010-06-30	0.36	0.37	0.01	2
2010-05-04	2010-03-31	0.38	0.38	0.0	0
2010-02-01	2009-12-31	0.36	0.36	0.0	0
2009-11-02	2009-09-30	0.32	0.35	0.03	9
2009-08-03	2009-06-30	0.33	0.35	0.02	6
2009-05-04	2009-03-31	0.32	0.33	0.01	3
2009-02-02	2008-12-31	0.3	0.32	0.02	6
2008-10-27	2008-09-30	0.26	0.29	0.03	11
2008-08-01	2008-06-30	0.27	0.3	0.03	11
2008-05-01	2008-03-31	0.29	0.29	0.0	0
2008-01-31	2007-12-31	0.27	0.28	0.01	3
2007-11-01	2007-09-30	0.23	0.23	0.0	0
2007-08-02	2007-06-30	0.25	0.25	0.0	0
2007-05-02	2007-03-31	0.26	0.36	0.1	38
2007-01-31	2006-12-31	0.24	0.25	0.01	4
2006-10-31	2006-09-30	0.22	0.2	-0.02	9
2006-07-27	2006-06-30	0.25	0.22	-0.03	12
2006-05-03	2006-03-31	0.28	0.31	0.03	10
2006-01-30	2005-12-31	0.23	0.25	0.02	8
2005-10-27	2005-09-30	0.19	0.2	0.01	5
2005-07-28	2005-06-30	0.19	0.24	0.05	26
2005-05-05	2005-03-31	0.18	0.19	0.01	5
2005-01-31	2004-12-31	0.18	0.23	0.05	27
2004-11-01	2004-09-30	0.17	0.17	0.0	0
2004-07-29	2004-06-30	0.19	0.19	0.0	0
2004-05-03	2004-03-31	0.19	0.19	0.0	0
2004-01-22	2003-12-31	0.17	0.19	0.02	11
2003-10-23	2003-09-30	0.14	0.12	-0.02	14
2003-07-24	2003-06-30	0.12	0.11	-0.01	8
2003-04-23	2003-03-31	0.12	0.09	-0.03	25
2003-01-23	2002-12-31	0.17	0.21	0.04	23
2002-10-24	2002-09-30	0.13	0.14	0.01	7
2002-07-24	2002-06-30	0.13	0.13	0.0	0
2002-05-02	2002-03-31	0.14	0.14	0.0	0
2002-01-24	2001-12-31	0.17	0.18	0.01	5
2001-10-25	2001-09-30	0.14	0.19	0.05	35
2001-07-26	2001-06-30	0.15	0.19	0.04	26
2001-05-03	2001-03-31	0.14	0.14	0.0	0
2001-01-25	2000-12-31	0.15	0.17	0.02	13
2000-10-26	2000-09-30	0.14	0.13	-0.01	7
2000-07-27	2000-06-30	0.13	0.13	0.0	0
2000-05-04	2000-03-31	0.14	0.14	0.0	0
2000-01-27	1999-12-31	0.13	0.13	0.0	0
1999-10-28	1999-09-30	0.1	0.11	0.01	10
1999-07-29	1999-06-30	0.09	0.11	0.02	22
1999-05-06	1999-03-31	0.09	0.12	0.03	33
1999-01-29	1998-12-31	0.1	0.09	-0.01	10
1998-10-26	1998-09-30	0.08	0.1	0.02	25
1998-07-27	1998-06-30	0.08	0.1	0.02	25
1998-05-04	1998-03-31	0.11	-0.06	-0.17	154
1998-01-27	1997-12-31	0.11	0.09	-0.02	18
1997-10-16	1997-09-30	0.11	0.08	-0.03	27
1997-04-15	1997-03-31	0.13	0.14	0.01	7
1997-01-14	1996-12-31	0.13	0.13	0.0	0
1996-10-11	1996-09-30	0.17	0.16	-0.01	5
1996-07-15	1996-06-30	0.16	0.17	0.01	6
1996-04-18	1996-03-31	0.17	0.17	0.0	0
1996-01-15	1995-12-31	0.16	0.16	0.0	0
1995-10-15	1995-09-30	0.16	0.17	0.01	6
1995-07-16	1995-06-30	0.16	0.16	0.0	0

Use Haemonetics in pair-trading

Pair analysis around Haemonetics matters because it can turn one security idea into a more market-neutral structure. Used properly, pair trading is less about prediction in isolation and more about identifying relative mispricing between related positions.

Haemonetics Pair Trading

Haemonetics Pair Trading Analysis

Finding closely correlated positions to Haemonetics provides context for tax-loss harvesting analysis. Selling Haemonetics at a loss and repurchasing it immediately would violate IRS wash-sale rules.

The correlation of Haemonetics is a statistical measure of how it moves in relation to other instruments. Values near +1 indicate near-identical movement to Haemonetics, while values near -1 suggest inverse movement.

Pair evaluation and Correlation analysis for Haemonetics provide hedging context. The information reflects structured market data collected across trading periods.

Pair Correlation Correlation Matching

Use Investing Themes to Complement your Haemonetics position

With 2.74 Billion market cap in the Medical Instruments & Supplies industry, Haemonetics works well as a smaller-cap core holding around which broader thematic baskets can be built. Haemonetics smaller-cap scale (2.74 Billion) within Medical Instruments & Supplies helps compare substitutes, complements, and diversifiers that strengthen the overall Healthcare allocation.

Did You Try This Idea?

Run Soft Drinks Thematic Idea Now

Soft Drinks

Entities manufacturing and distributing non alcoholic beverages across different markets. The Soft Drinks theme has 12 constituents at this time.

The Soft Drinks Theme can be deployed as a buy-and-hold allocation or traded actively around individual position volatility.

View All Next

Launch

More Resources for Haemonetics Stock Analysis

A broader look at Haemonetics comes from its financial reports and historical data. Highlighted below are reports that provide context for Haemonetics Stock:

How To Invest In Haemonetics

Details

Is Haemonetics Stock a good investment?

Details

What is Haemonetics' Net Worth?

Details

Largest Health Care Equipment & Supplies Companies

View

Largest Health Care Equipment & Services Companies

View

Macroaxis provides analytical tools and reference data for investors of all levels to evaluate holdings and assess risk across market volatility, economic shifts, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2026 Macroaxis LLC

	Revenue vs Return On Equity
	Return On Asset vs Net Income
	Revenue vs Profit Margin
	Operating Margin vs Net Income
	Revenue vs Current Valuation
	Shares Outstanding vs Net Income
	Revenue vs Shares Owned By Insiders
	Shares Owned By Institutions vs Net Income
	Revenue vs Number Of Shares Shorted
	Price To Earning vs Net Income
	Revenue vs Price To Book
	Price To Sales vs Net Income
	Revenue vs Gross Profit
	EBITDA vs Net Income
	Revenue vs Cash And Equivalents

Haemonetics Revenue vs. Net Income

Revenue by Earning Segment

Haemonetics Revenue by Earnings Segment Overview

Haemonetics Net Income vs. Revenue Fundamental Analysis

Haemonetics Revenue vs. Competition

Haemonetics Net Income vs. Revenue

Haemonetics

Revenue

Money Received

-

Discounts and Returns

Haemonetics

Net Income

(Rev + Gain)

-

(Exp + Loss)

Haemonetics Net Income Comparison

Haemonetics Profitability Projections

Haemonetics Profitability Driver Comparison

Earnings Estimation Breakdown

Earnings Projection Consensus

Earnings History

Haemonetics Quarterly Gross Profit

Earnings per Share Projection vs Actual

Estimated Months Earnings per Share

Quarterly Analyst Estimates and Surprise Metrics

Use Haemonetics in pair-trading

Haemonetics Pair Trading

Haemonetics Pair Trading Analysis

Use Investing Themes to Complement your Haemonetics position

Did You Try This Idea?

Run Soft Drinks Thematic Idea Now

Soft Drinks

More Resources for Haemonetics Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY